{"id":371183,"date":"2024-02-02T00:01:00","date_gmt":"2024-02-01T23:01:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=371183"},"modified":"2024-01-24T17:31:38","modified_gmt":"2024-01-24T16:31:38","slug":"semaglutide-in-oral-form-convinces-in-everyday-practice","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/semaglutide-in-oral-form-convinces-in-everyday-practice\/","title":{"rendered":"Semaglutide in oral form convinces in everyday practice"},"content":{"rendered":"\n

In the non-interventional PIONEER REAL Switzerland study, adult type 2 diabetics treated with oral semaglutide as part of routine clinical care achieved clinically significant improvement in glycemic control with no new safety signals. The results were presented at the SGED Annual Meeting and underpin the promising results of the clinical approval studies.<\/strong><\/p>\n\n\n\n

Semaglutide has also been on the market in Switzerland for the treatment of type 2 diabetes (T2D) in oral form since 2020 \u2013 under the trade name Rybelsus\u00ae [1]. Like other glucagon-like peptide-1 receptor agonists (GLP-1-RA), semaglutide binds to the GLP-1 receptor, thereby promoting insulin secretion and inhibiting glucagon secretion. The Phase III PIONEER trial program was very successful. One of the main studies showed that Rybelsus\u00ae not only improves metabolic control and reduces body weight, but also results in fewer heart attacks and even fewer deaths[1,2]. The aim of the international Phase IV study PIONEER REAL is to systematically observe how the drug works and is tolerated under everyday conditions [2]. <\/p>\n\n

Multicenter real-world study<\/h3>\n\n

PIONEER REAL Switzerland is part of a study project conducted in 13 countries – it is a 34-44-week single-arm, prospective open-label multicenter study in adults with T2D. Participants were treatment-naive to glucose-lowering injection therapies at baseline and received semaglutide in oral form once daily as part of their usual routine care [3]. In addition to changes in HbA1c<\/sub> (primary endpoint) and body weight (secondary endpoint), the proportion of patients who achieved HbA1c<\/sub> <7% and\/or a composite endpoint of an HbA1c<\/sub> reduction \u22651% accompanied by a reduction in body weight (BW) \u22653% or \u22655% at the end of the study was recorded. <\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n

Important results at a glance <\/h3>\n\n

Of the 185 participants included, 90.8% completed the study and 77.3% remained on semaglutide therapy until the end of the study [3]. At baseline, the average age was 62 (SD 10.4) years, the HbA1c<\/sub> value was 7.7% (SD 1.5%) and the body weight was 95.6 kg (SD 17.6 kg). The mean BMI was documented as 33.2 kg\/m2<\/sup> (4.8 kg\/m2<\/sup>). 56.2% of the participants received other glucose-lowering medication at the same time. <\/p>\n\n

** SD = standard deviation<\/em>KI=confidence interval<\/p>\n\n

The estimated mean changes from baseline to the end of the study were as follows [3]: <\/p>\n\n